<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34558001</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1940-6029</ISSN><JournalIssue CitedMedium="Internet"><Volume>2389</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Methods in molecular biology (Clifton, N.J.)</Title><ISOAbbreviation>Methods Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Culturing and Expansion of "Clinical Grade" Neural Stem Cells from the Fetal Human Central Nervous System.</ArticleTitle><Pagination><StartPage>57</StartPage><EndPage>66</EndPage><MedlinePgn>57-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-0716-1783-0_5</ELocationID><Abstract><AbstractText>NSCs have been demonstrated to be very useful in grafts into the mammalian central nervous system to investigate the exploitation of NSC for the therapy of neurodegenerative disorders in animal models of neurodegenerative diseases. To push cell therapy in CNS on stage of clinical application, it is necessary to establish a continuous and standardized, clinical grade (i.e., produced following the good manufacturing practice guidelines) human neural stem cell lines.In this chapter we will illustrate some of the protocols for the production and characterization routinely used into our GMP "cell factory" for the production of "clinical grade" human neural stem cell lines already in use in clinical trials on neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS- Clinicaltrials.gov number NCT01640067) and secondary progressive multiple sclerosis (SPMS- Clinicaltrials.gov number NCT03282760).</AbstractText><CopyrightInformation>&#xa9; 2022. Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gelati</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy. m.gelati@operapadrepio.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Profico</LastName><ForeName>Daniela Celeste</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vescovi</LastName><ForeName>Angelo Luigi</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy. vescovia@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03282760</AccessionNumber><AccessionNumber>NCT01640067</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Methods Mol Biol</MedlineTA><NlmUniqueID>9214969</NlmUniqueID><ISSNLinking>1064-3745</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="Y">Neural Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical grade</Keyword><Keyword MajorTopicYN="N">Human central nervous system</Keyword><Keyword MajorTopicYN="N">Neural stem cells</Keyword><Keyword MajorTopicYN="N">Precursor cells</Keyword><Keyword MajorTopicYN="N">Therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>24</Day><Hour>7</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34558001</ArticleId><ArticleId IdType="doi">10.1007/978-1-0716-1783-0_5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reynolds BA, Weiss S (1992) Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255(5052):1707&#x2013;1710</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1553558</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboody K, Capela A, Niazi N et al (2011) Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone. Neuron 70(4):597&#x2013;613</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.05.007</ArticleId></ArticleIdList></Reference><Reference><Citation>de Filippis L (2011) Neural stem cell-mediated therapy for rare brain diseases: perspectives in the near future for LSDs and MNDs. Histol Histopathol 26(8):1093&#x2013;1010</Citation><ArticleIdList><ArticleId IdType="pubmed">21692041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SU, de Vellis J (2009) Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Res 87(10):2183&#x2013;2200</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22054</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindvall O, Kokaia Z (2010) Stem cells in human neurodegenerative disorders&#x2014;time for clinical translation? J Clin Invest 120(1):29&#x2013;40</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI40543</ArticleId></ArticleIdList></Reference><Reference><Citation>Vescovi AL, Parati EA, Gritti A et al (1999) Isolation and cloning of multipotential stem cells from the embryonic human CNS and establishment of transplantable human neural stem cell lines by epigenetic stimulation. Exp Neurol 156(1):71&#x2013;83</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1998.6998</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelati M, Profico D, Projetti-Pensi M et al (2013) Culturing and expansion of &#x201c;clinical grade&#x201d; precursors cells from the fetal human central nervous system. Methods Mol Biol 1059:65&#x2013;77</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-574-3_6</ArticleId></ArticleIdList></Reference><Reference><Citation>EU GMP, EudraLex the rules governing medicinal products in the European Union, vol 4: good manufacturing practice guidelines on good manufacturing practice specific to advanced therapy medicinal products, current edition</Citation></Reference><Reference><Citation>Mazzini L, Gelati M, Profico DC et al (2019) Results from phase I clinical trial with intraspinal injection of neural stem cells in amyotrophic lateral sclerosis: a long-term outcome. Stem Cells Transl Med 8(9):887&#x2013;897</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sctm.18-0154</ArticleId></ArticleIdList></Reference><Reference><Citation>European Pharmacopeia, 10th edn (published 2020)</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>